Table 4.
miRNA signatures for prognosis and treatment response in HER+ breast cancer subtypes
| miRNA(s) | Patient cohort | Sample | Methodology | Clinical observation(s) | Reference |
|---|---|---|---|---|---|
| miR-21 | 32 Stage III HER2+ cases (ER+ [56.2%] vs ER− [43.8%]) | Frozen tissues (pre- and post-neoadjuvant treatment) | TaqMan qRT-PCR (Thermo Fisher Scientific) | Higher levels correlate with poor treatment response. | 79 |
| miR-21, miR-210, miR-373 | 127 HER2+ cases (ER+ [56%] vs ER− [44%]; LN− [40%] vs LN+ [60%]; M0 [84%] vs M1 [16%]) with neoadjuvant treatment (trastuzumab [50%] vs lapatinib [50%]) | Serum (pre- and post-neoadjuvant treatment) | TaqMan qRT-PCR (Thermo Fisher Scientific) | No correlation with pathologic complete response. High levels of miR-21 correlate with overall survival. | 120 |
| miR-210 | 29 HER2+ cases (ER+ [44.8%] vs ER− [55.2%]; LN− [34.4%] vs LN+ [65.6%]; with neoadjuvant treatment (trastuzumab + chemotherapy) | Plasma (pre- and post-neoadjuvant treatment) | TaqMan qRT-PCR (Thermo Fisher Scientific) | Higher circulating levels correlate with pathologic complete response, tumor presence, and LN+ status. | 119 |
Abbreviations: ER, estrogen receptor; HER2, human EGF-like receptor 2; miRNA, microRNA; LN, lymph node status; qRT-PCR, quantitative real-time polymerase chain reaction.